Gilead Scraps HR-MDS Trial; FDA OKs Verrica's Molluscum Treatment
- July 22nd, 2023
- 465 views
Gilead Sciences, Inc. (Nasdaq: GILD) announced the termination of the Phase 3 ENHANCE study evaluating magrolimab plus azacitidine as a first-line treatment for higher-risk myelodysplastic syndromes (HR-MDS) due to futility based on a planned analysis.
The safety data observed in this study aligns with the established magrolimab profile and the usual adverse events found in this patient population, prompting Gilead's recommendation to discontinue magrolimab treatment for MDS patients.
On Friday, $GILD closed at $80.64, reflecting a gain of $0.70 (+0.88%)
In other news, Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) gained U.S. FDA approval for YCANTH (cantharidin) topical solution to treat molluscum contagiosum (molluscum) in adult and pediatric patients aged 2 years and older.
Molluscum is a highly contagious viral skin infection, mainly affecting children. YCANTH, a drug-device combination product, is expected to be available through healthcare professionals by September 2023.
$VRCA closed at $7.45 on Friday, up $0.28 (+3.83%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Countdown to Earnings: Nutanix, CrowdStrike, and Synopsys on Deck
August 23rd, 2026Investors Eye Semtech, Intuit, and nCino as Earnings Loom
August 22nd, 2026FTC Files Amicus Brief to Protect Competition in Biologic Drug Markets
August 21st, 2026
Member Login